Samuel R Kaufman
Overview
Explore the profile of Samuel R Kaufman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
94
Citations
976
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Srivastava A, Kaufman S, Shay A, Oerline M, Liu X, Van Til M, et al.
JAMA Netw Open
. 2025 Jan;
8(1):e2453658.
PMID: 39775806
Importance: Active surveillance in men with less aggressive prostate cancer is inconsistently used despite clinical guidelines. Renumeration generally favors treatment over conservative management and may contribute to the variable adoption...
2.
Faraj K, Kaufman S, Oerline M, Dall C, Srivastava A, Caram M, et al.
Cancer Med
. 2024 Dec;
14(1):e70552.
PMID: 39739625
Introduction: Oral targeted therapies are a standard of care for men with advanced prostate cancer. However, these therapies are expensive, which may be a barrier to some, particularly the most...
3.
Dall C, Liu X, Faraj K, Srivastava A, Kaufman S, Hartman N, et al.
Cancer Med
. 2024 Dec;
13(23):e70436.
PMID: 39624952
Introduction And Objectives: Prior work has demonstrated racial disparities in surgical outcomes for solid organ cancers. We sought to assess the relationship between hospital quality and racial disparities in achievement...
4.
Maganty A, Kaufman S, Oerline M, Faraj K, Caram M, Ryan A, et al.
Urology
. 2024 Nov;
196:137-144.
PMID: 39581508
Objective: To examine the relationship between market dynamics, in the form of commercial prices paid to urologists, and utilization of services, as measured by Medicare spending, in men with newly...
5.
Srivastava A, Liu X, Maganty A, Kaufman S, Shay A, Oerline M, et al.
Cancer
. 2024 Nov;
131(1):e35633.
PMID: 39501423
Background: For men with prostate cancer, there is substantial variation in the use of conservative management, such as active surveillance. Commercial prices, which vary across urology practices, may afford incentives...
6.
Faraj K, Oerline M, Kaufman S, Dall C, Srivastava A, Caram M, et al.
Urol Pract
. 2024 Aug;
11(6):931-938.
PMID: 39196717
Introduction: The use of expensive oral targeted agents for advanced prostate cancer can be influenced by those who stand to gain from their use. The 340B drug pricing program allows...
7.
Faraj K, Oerline M, Kaufman S, Dall C, Srivastava A, Caram M, et al.
J Natl Cancer Inst
. 2024 Jul;
116(11):1817-1824.
PMID: 39049442
Background: The use of androgen biosynthesis and second-generation androgen receptor inhibitors for advanced prostate cancer is increasing. Because these therapies alter the androgen pathway, they have been associated with cardiometabolic...
8.
Dall C, Liu X, Faraj K, Srivastava A, Kaufman S, Shahinian V, et al.
Urology
. 2024 Jun;
191:64-70.
PMID: 38878826
Objective: To assess textbook outcomes by hospital teaching status following major surgery for urologic cancers. Methods: We used 100% national Medicare Provider Analysis and Review files from 2017-2020 to assess...
9.
Faraj K, Kaufman S, Oerline M, Herrel L, Maganty A, Caram M, et al.
Cancer
. 2024 Feb;
130(12):2160-2168.
PMID: 38395607
Introduction: Expensive oral specialty drugs for advanced prostate cancer can be associated with treatment disparities. The 340B program allows hospitals to purchase medications at discounts, generating savings that can improve...
10.
Maganty A, Kaufman S, Oerline M, Faraj K, Caram M, Shahinian V, et al.
Cancer Med
. 2023 Dec;
13(1):e6810.
PMID: 38146905
Objective: To examine the effect of urologist participation in value-based payment models on the initial management of men with newly diagnosed prostate cancer. Methods: Medicare beneficiaries with prostate cancer diagnosed...